Aytu BioPharma (NASDAQ:AYTU) Stock Passes Below Two Hundred Day Moving Average – Here’s Why

Aytu BioPharma, Inc. (NASDAQ:AYTU)’s share price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.36 and traded as low as $1.40. Aytu BioPharma shares last traded at $1.44, with a volume of 12,010 shares changing hands.

Aytu BioPharma Trading Up 2.5 %

The stock has a fifty day moving average of $1.82 and a two-hundred day moving average of $2.36. The company has a market capitalization of $8.82 million, a PE ratio of -1.17 and a beta of -1.40. The company has a current ratio of 0.99, a quick ratio of 0.80 and a debt-to-equity ratio of 0.35.

Aytu BioPharma (NASDAQ:AYTU) last posted its quarterly earnings results on Thursday, September 26th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.37). Aytu BioPharma had a negative return on equity of 21.89% and a negative net margin of 8.28%. The business had revenue of $17.98 million for the quarter.

Institutional Trading of Aytu BioPharma

Institutional investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP lifted its stake in shares of Aytu BioPharma by 54.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 23,551 shares of the company’s stock valued at $69,000 after acquiring an additional 8,311 shares during the last quarter. Armistice Capital LLC purchased a new position in Aytu BioPharma in the 2nd quarter worth approximately $736,000. Finally, Stonepine Capital Management LLC lifted its position in Aytu BioPharma by 6.0% in the third quarter. Stonepine Capital Management LLC now owns 500,958 shares of the company’s stock valued at $1,177,000 after purchasing an additional 28,489 shares during the last quarter. 33.49% of the stock is currently owned by hedge funds and other institutional investors.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.